IDEXX Laboratories, Inc. $IDXX Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC decreased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 75.5% in the 1st quarter, Holdings Channel.com reports. The firm owned 10,631 shares of the company’s stock after selling 32,794 shares during the quarter. SG Americas Securities LLC’s holdings in IDEXX Laboratories were worth $5,973,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Virtus Advisers LLC acquired a new position in shares of IDEXX Laboratories in the 3rd quarter valued at $26,000. SHP Wealth Management acquired a new stake in IDEXX Laboratories during the 4th quarter worth $26,000. Park Place Capital Corp acquired a new stake in IDEXX Laboratories during the 4th quarter worth $29,000. WealthCollab LLC purchased a new stake in IDEXX Laboratories in the second quarter valued at $30,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in IDEXX Laboratories in the third quarter valued at $36,000. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $551.50 on Monday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The company has a market capitalization of $43.50 billion, a P/E ratio of 40.61, a PEG ratio of 3.02 and a beta of 1.56. IDEXX Laboratories, Inc. has a 1 year low of $506.91 and a 1 year high of $769.98. The company’s fifty day moving average is $558.79 and its two-hundred day moving average is $614.13.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

Wall Street Analysts Forecast Growth

IDXX has been the topic of several research reports. Citigroup started coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective on the stock. Wall Street Zen raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. UBS Group decreased their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday. Finally, Stifel Nicolaus cut their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Seven analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.